Kantar has launched an online platform using anonymized and aggregated patient data to track changes, delays and modifications to cancer treatment decisions during the Covid-19 crisis.
Health data gathered during the pandemic shows that cancer diagnosis and treatments have been interrupted, with screenings and falls in admissions for chemotherapy down, and urgent referrals for early cancer diagnosis, in some cases, halted. The new Kantar Oncology Platform provides a solution to monitor changes in treatment during the crisis, enabling physicians involved in cancer patient care across France, Germany, Italy, Spain, the UK and the US to view how specific patients' profiles are being cared for during this crisis. Participating physicians can filter the data by country, tumor type, comorbidities, patient profile (age, performance status), and treatment(s).
Julien Goretti (pictured), Brand Research Lead at Kantar Health, comments: 'We created this platform after hearing concerns from oncologists and related specialists that they lack sufficient data to make informed decisions during the current medical crisis. Since launch, more than 300 physicians have connected to the platform and gained access to aggregated data for nearly 1000 patients. We look forward to providing continued support to the oncology community during this crisis'.
Web site: www.kantar.com .
All articles 2006-21 written and edited by Mel Crowther and/or Nick Thomas unless otherwise stated.